AI and machine learning key enablers of healthcare value, expert panel says

MIT NEWDIGS Director and advisor speak at LIGHT Forum on AI in Healthcare

CAMBRIDGE, MASSACHUSETTS—MIT NEW Drug Development ParadIGmS (NEWDIGS) director Dr Gigi Hirsch, and program advisor R. John Glasspool spoke this week at the inaugural Leaders in Global Health & Technology (LIGHT) Forum hosted by Stanford Medical School in California. NEWDIGS is an international “think […]

MIT NEWDIGS Hosts Design Lab on New Gene and Oncology Therapy Financing Models

Industry leaders, patient advocates, policymakers collaborate to lower barriers to potentially curative treatments

CAMBRIDGE, MASSACHUSETTS—The MIT NEW Drug Development ParadIGmS (NEWDIGS) initiative, an international biomedical innovation “think and do tank” involving a range of stakeholders in the healthcare system, hosted a collaborative Design Lab to explore ways to make potentially curative—but expensive—therapies available to patients as […]

Dr Gigi Hirsch and John Glasspool to speak at LIGHT Forum

MIT NEWDIGS director Dr Gigi Hirsch and her colleague R. John Glasspool will address the LIGHT Forum on the impact of artificial intelligence and Big Data on healthcare. They will explore the evolution from an emphasis on efficacy to a focus on value, and how all healthcare stakeholders can collaborate to improve outcomes for all […]

Hilary Malone joins MIT NEWDIGS Executive Committee

Regulatory and business leader will help accelerate system-wide biomedical innovation

Dr Hilary MaloneCAMBRIDGE, MASSACHUSETTS, 1 MARCH 2017—The MIT New Drug Development Paradigms Initiative (NEWDIGS) announced today that Hilary Malone, Chief Regulatory Officer for pharmaceutical company Sanofi, has joined the NEWDIGS Executive Committee. Sanofi is a strategic partner of […]

MIT NEWDIGS Hosts Design Lab on Clinical Trial Innovation

Biomedical Innovation Initiative Supporting New NIH-Funded Trial Innovation Center

CAMBRIDGE, MASSACHUSETTS—The MIT NEW Drug Development ParadIGmS (NEWDIGS) initiative, an international biomedical innovation “think and do tank”, co-hosted an “Efficacy to Effectiveness Clinical Trial” Design Lab in partnership with the Tufts Clinical Translational Science Institute (CTSI) and the new Johns Hopkins University (JHU) – Tufts Medical Center […]

Kay Larholt joins MIT NEWDIGS as Director of Integrated Knowledge Solutions

Industry veteran will lead development of new decision support technologies

CAMBRIDGE, MASSACHUSETTS—The MIT New Drug Development Paradigms Initiative (NEWDIGS) announced today the hire of Dr. Kay M. Larholt as their Director of Integrated Knowledge Solutions. Dr. Larholt will lead a portfolio of activities focused on “Knowledge Generation and Use 2.0,” a critical component of Adaptive Biomedical […]

OpEd: Mark Trusheim & Peter B. Bach on How the US Can Beat Hepatitis C

How the US Can Beat Hepatitis C: Don’t buy the pills, buy the company
Pharma veteran and physician advance provocative solution to overcome treatment costs

CAMBRIDGE, MASSACHUSETTS—In an article published today in Forbes, Visiting Scientist at the MIT Sloan School of Management Mark Trusheim and co-author Peter B. Bach, a physician at Memorial Sloan Kettering Cancer […]

Special Issue of Clinical Pharmacology & Therapeutics spotlights Adaptive Biomedical Innovation

Expert views on strategies for getting new science to patients faster, safely, and affordably

CAMBRIDGE, Mass., Nov. 9, 2016—Clinical Pharmacology & Therapeutics (CPT), a cross-disciplinary journal in experimental and clinical medicine, in collaboration with the MIT Center for Biomedical Innovation (CBI) and its New Drug Development Paradigms (NEWDIGS) initiative, published a special issue today focusing on […]

NEWDIGS convenes healthcare leaders to pioneer new pharmaceutical financing strategies

CAMBRIDGE, Mass., Oct. 27, 2016 — Patient advocates, healthcare payers, industry, and academic stakeholders gathered today at the Massachusetts Institute of Technology (MIT) to map out a new strategy for designing and piloting innovative financing and reimbursement models for promising, and possibly curative, new medicines. The project is called Financing and Reimbursement of Cures in […]

European Rare Diseases advocate EURORDIS joins as NEWDIGS member

International collaboration aims to improve healthcare for people living with a rare disease

BOSTON, PARIS, 1 JULY 2016—MIT’s NEW Drug Development ParadIGmS (NEWDIGS) program announced today that EURORDIS-Rare Diseases Europe, the European Organisation for Rare Diseases, has joined its international effort to accelerate delivery of new, better, affordable therapeutics to patients faster. NEWDIGS brings together pharmaceutical and biotech companies, regulators, insurers, patient advocacy groups, and other healthcare stakeholders to design modern systems that connect scientific discovery to patient care. […]